Laboratory testing for cytomegalovirus among pregnant women in the United States: a retrospective study using administrative claims data

Table 3 Association between CMV-specific testing ^a by selected factors, pregnant women ^b , MarketScan 2009

Factor	Pregnant women^b
	Total	# Tested	% Tested	p-Value
Age Group (years)
15-19	2,955	22	0.7%	<0.001
20-29	30,819	519	1.7%
30-39	40,815	1,022	2.5%
40-44	3,184	105	3.3%
Urban Residence
No	10,592	65	0.6%	<0.001
Yes	67,181	1,603	2.4%
Region ^c
Northeast	9,674	628	6.5%	<0.001
North Central	21,206	313	1.5%
South	34,781	579	1.7%
West	11,970	148	1.2%
Diagnostic Code for Infectious Mononucleosis ^d
No	77,729	1,662	2.1%	<0.001
Yes	44	6	13.6%

Note: CMV, cytomegalovirus; PCR, polymerase chain reaction; IgG, Immunoglobulin G; IgM, Immunoglobulin M; DFA, direct fluorescent testing; EIA, enzyme immunoassay; ICD-9-CM, International Classification of Diseases-9^th revision, Clinical Modification.
^aCMV-specific testing includes CMV IgG, CMV IgM, CMV DFA, CMV EIA, and CMV PCR testing.
^bPregnant women defined as female enrollees who were 1) aged 15–44 years, 2) enrolled for the entire year in 2009, and 3) had a delivery code (defined in Appendix) between October-December 2009.
^cExcludes those pregnant women with other or unknown information on region.
^dA diagnosis of mononucleosis was defined by an ICD-9-CM code for infectious mononucleosis (ICD-9-CM 075).

ISSN: 1471-2334